Fennec Pharmaceuticals Inc.
FENC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001211583
In the last 90 days, Fennec Pharmaceuticals Inc. insiders filed 0 open-market purchases and 4 sales; 105 institutions reported holding it in 13F filings for Q2 2026, worth $175.1M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 12, 2026
- $384.8M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.31M in total
- 4
- 13F holdersQ2 2026, +17 vs. previous quarter
- 105
- 13F valueReported value at the end of Q2 2026
- $175.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $44.6M
- −6.1% year over year
- Net income, FY2025
- -$9.74M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- $19.6M
- +57.3% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $9.74M (21.8% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 454.5K
- Shares sold short
- Change
- −33.1K
- −6.8% vs. previous
- Days to cover
- 3.89
- At average daily volume
Superinvestors holding FENC, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding FENC at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Fennec Pharmaceuticals Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 16, 2026 (view filing)4:05 PM ET | Sep 15 | 1 day | Brughera Marco MariaDirector | SSale | −15.5K | $10.29 | −$160.0K | −100.0%0 after | 10b5-1 |
| Sep 1, 2026 (view filing)4:05 PM ET | Sep 1 | Same day | Raykov RostyOther: Former Director | SSale | −10.0K | $12.11 | −$121.1K | −7.4%124.4K after | 10b5-1 |
| Aug 31, 2026 (view filing)8:15 PM ET | Aug 31 | Same day | Sayad Pierre SargisChief Medical Officer | SSale | −12.0K | $12.18 | −$146.2K | −55.8%9.52K after | |
| Aug 28, 2026 (view filing)5:42 PM ET | Aug 27 | 1 day | Andrade RobertCHIEF FINANCIAL OFFICER | SSale | −75.0K | $11.78 | −$883.5K | −25.6%217.7K after | 10b5-1 |
| Aug 4, 2026 (view filing)4:05 PM ET | Aug 3 | 1 day | Raykov RostyOther: Former Director | SSale | −10.0K | $9.58 | −$95.8K | −7.1%131.6K after | 10b5-1 |
| Jul 2, 2026 (view filing)4:05 PM ET | Jul 1 | 1 day | Raykov RostyOther: Former Director | SSale | −9.60K | $10.41 | −$99.9K | −6.5%138.9K after | 10b5-1 |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Raykov RostyDirector | SSale | −9.75K | $9.62 | −$93.8K | −7.0%130.1K after | 10b5-1 |
| May 12, 2026 (view filing) | May 11 | 1 day | Rallis Chris ADirector | SSale | −8.35K | $7.04 | −$58.8K | −11.7%63.1K after | 10b5-1 |
| May 1, 2026 (view filing) | May 1 | Same day | Raykov RostyDirector | SSale | −10.8K | $6.47 | −$69.8K | −8.2%121.5K after | 10b5-1 |
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Raykov RostyDirector | SSale | −10.9K | $6.31 | −$69.1K | −8.8%113.9K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 105 holdersThe largest institutional positions in Fennec Pharmaceuticals Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 3,188,001 | $34.3M | 12.87% | +279,800+9.6% | Added |
| AIGH Capital Management LLC | 2,486,038 | $26.7M | 2.42% | +504,537+25.5% | Added |
| Solas Capital Management, LLC | 1,889,366 | $20.3M | 10.88% | −592,832−23.9% | Reduced |
| BlackRock, Inc. | 1,727,069 | $18.6M | 0.00% | +358,893+26.2% | Added |
| AWM Investment Company, Inc. | 1,160,296 | $12.5M | 1.08% | +440,161+61.1% | Added |
| Vanguard Capital Management LLC | 839,306 | $9.02M | 0.00% | −57,838−6.4% | Reduced |
| Prospect Capital Advisors, LLC | 497,800 | $5.35M | 2.43% | +497,800 | New |
| State Street Corp | 426,004 | $4.58M | 0.00% | +66,949+18.6% | Added |
| Geode Capital Management, LLC | 402,566 | $4.33M | 0.00% | +30,828+8.3% | Added |
| Jane Street Group, LLC | 233,877 | $2.51M | 0.00% | +233,877 | New |
Holders of 5% or more of FENC
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Fennec Pharmaceuticals Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 13G/A | 9.60%3.32M shares | +0.80 ppfrom 8.80% | Nov 13, 20254 filings | Aug 13, 2026 | SEC |
| Sonic Fund II, L.P. | 13G/A | 8.20%2.80M shares | – | Feb 16, 20213 filings | Feb 17, 2026 | SEC |
| Hirschman Orin | 13G/A | 7.10%2.50M shares | +1.40 ppfrom 5.70% | Apr 28, 20262 filings | Oct 19, 2026 | SEC |
| Solas Capital Management, LLC | 13G/A | 5.40%1.89M shares | −1.80 ppfrom 7.20% | Feb 14, 20245 filings | Aug 14, 2026 | SEC |